Search

Your search keyword '"Nkengasong, J."' showing total 214 results
Start Over Author "Nkengasong, J."
214 results on '"Nkengasong, J."'

1. The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

Author

Tegally, H, San, JE, Cotten, M, Moir, M, Tegomoh, B, Mboowa, G, Martin, DP, Baxter, C, Lambisia, AW, Diallo, A, Amoako, DG, Diagne, MM, Sisay, A, Zekri, A-RN, Gueye, AS, Sangare, AK, Ouedraogo, A-S, Sow, A, Musa, AO, Sesay, AK, Abias, AG, Elzagheid, A, Lagare, A, Kemi, A-S, Abar, AE, Johnson, AA, Fowotade, A, Oluwapelumi, AO, Amuri, AA, Juru, A, Kandeil, A, Mostafa, A, Rebai, A, Sayed, A, Kazeem, A, Balde, A, Christoffels, A, Trotter, AJ, Campbell, A, Keita, AK, Kone, A, Bouzid, A, Souissi, A, Agweyu, A, Naguib, A, Gutierrez, A, Nkeshimana, A, Page, AJ, Yadouleton, A, Vinze, A, Happi, AN, Chouikha, A, Iranzadeh, A, Maharaj, A, Batchi-Bouyou, AL, Ismail, A, Sylverken, AA, Goba, A, Femi, A, Sijuwola, AE, Marycelin, B, Salako, BL, Oderinde, BS, Bolajoko, B, Diarra, B, Herring, BL, Tsofa, B, Lekana-Douki, B, Mvula, B, Njanpop-Lafourcade, B-M, Marondera, BT, Khaireh, BA, Kouriba, B, Adu, B, Pool, B, McInnis, B, Brook, C, Williamson, C, Nduwimana, C, Anscombe, C, Pratt, CB, Scheepers, C, Akoua-Koffi, CG, Agoti, CN, Mapanguy, CM, Loucoubar, C, Onwuamah, CK, Ihekweazu, C, Malaka, CN, Peyrefitte, C, Grace, C, Omoruyi, CE, Rafai, CD, Morang'a, CM, Erameh, C, Lule, DB, Bridges, DJ, Mukadi-Bamuleka, D, Park, D, Rasmussen, DA, Baker, D, Nokes, DJ, Ssemwanga, D, Tshiabuila, D, Amuzu, DSY, Goedhals, D, Grant, DS, Omuoyo, DO, Maruapula, D, Wanjohi, DW, Foster-Nyarko, E, Lusamaki, EK, Simulundu, E, Ong'era, EM, Ngabana, EN, Abworo, EO, Otieno, E, Shumba, E, Barasa, E, Ahmed, EB, Ahmed, EA, Lokilo, E, Mukantwari, E, Philomena, E, Belarbi, E, Simon-Loriere, E, Anoh, EA, Manuel, E, Leendertz, F, Taweh, FM, Wasfi, F, Abdelmoula, F, Takawira, FT, Derrar, F, Ajogbasile, F, Treurnicht, F, Onikepe, F, Ntoumi, F, Muyembe, FM, Ragomzingba, FEZ, Dratibi, FA, Iyanu, F-A, Mbunsu, GK, Thilliez, G, Kay, GL, Akpede, GO, van Zyl, GU, Awandare, GA, Kpeli, GS, Schubert, G, Maphalala, GP, Ranaivoson, HC, Omunakwe, HE, Onywera, H, Abe, H, Karray, H, Nansumba, H, Triki, H, Kadjo, HAA, Elgahzaly, H, Gumbo, H, Mathieu, H, Kavunga-Membo, H, Smeti, I, Olawoye, IB, Adetifa, IMO, Odia, I, Ben Boubaker, IB, Mohammad, IA, Ssewanyana, I, Wurie, I, Konstantinus, IS, Halatoko, JWA, Ayei, J, Sonoo, J, Makangara, J-CC, Tamfum, J-JM, Heraud, J-M, Shaffer, JG, Giandhari, J, Musyoki, J, Nkurunziza, J, Uwanibe, JN, Bhiman, JN, Yasuda, J, Morais, J, Kiconco, J, Sandi, JD, Huddleston, J, Odoom, JK, Morobe, JM, Gyapong, JO, Kayiwa, JT, Okolie, JC, Xavier, JS, Gyamfi, J, Wamala, JF, Bonney, JHK, Nyandwi, J, Everatt, J, Nakaseegu, J, Ngoi, JM, Namulondo, J, Oguzie, JU, Andeko, JC, Lutwama, JJ, Mogga, JJH, O'Grady, J, Siddle, KJ, Victoir, K, Adeyemi, KT, Tumedi, KA, Carvalho, KS, Mohammed, KS, Dellagi, K, Musonda, KG, Duedu, KO, Fki-Berrajah, L, Singh, L, Kepler, LM, Biscornet, L, Martins, LDO, Chabuka, L, Olubayo, L, Ojok, LD, Deng, LL, Ochola-Oyier, L, Tyers, L, Mine, M, Ramuth, M, Mastouri, M, ElHefnawi, M, Mbanne, M, Matsheka, M, Kebabonye, M, Diop, M, Momoh, M, Lima Mendonca, MDL, Venter, M, Paye, MF, Faye, M, Nyaga, MM, Mareka, M, Damaris, M-M, Mburu, MW, Mpina, MG, Owusu, M, Wiley, MR, Tatfeng, MY, Ayekaba, MO, Abouelhoda, M, Beloufa, MA, Seadawy, MG, Khalifa, MK, Matobo, MM, Kane, M, Salou, M, Mbulawa, MB, Mwenda, M, Allam, M, Phan, MVT, Abid, N, Rujeni, N, Abuzaid, N, Ismael, N, Elguindy, N, Top, NM, Dia, N, Mabunda, N, Hsiao, N-Y, Silochi, NB, Francisco, NM, Saasa, N, Bbosa, N, Murunga, N, Gumede, N, Wolter, N, Sitharam, N, Ndodo, N, Ajayi, NA, Tordo, N, Mbhele, N, Razanajatovo, NH, Iguosadolo, N, Mba, N, Kingsley, OC, Sylvanus, O, Femi, O, Adewumi, OM, Testimony, O, Ogunsanya, OA, Fakayode, O, Ogah, OE, Oludayo, O-E, Faye, O, Smith-Lawrence, P, Ondoa, P, Combe, P, Nabisubi, P, Semanda, P, Oluniyi, PE, Arnaldo, P, Quashie, PK, Okokhere, PO, Bejon, P, Dussart, P, Bester, PA, Mbala, PK, Kaleebu, P, Abechi, P, El-Shesheny, R, Joseph, R, Aziz, RK, Essomba, RG, Ayivor-Djanie, R, Njouom, R, Phillips, RO, Gorman, R, Kingsley, RA, Neto Rodrigues, RMDESA, Audu, RA, Carr, RAA, Gargouri, S, Masmoudi, S, Bootsma, S, Sankhe, S, Mohamed, SI, Femi, S, Mhalla, S, Hosch, S, Kassim, SK, Metha, S, Trabelsi, S, Agwa, SH, Mwangi, SW, Doumbia, S, Makiala-Mandanda, S, Aryeetey, S, Ahmed, SS, Ahmed, SM, Elhamoumi, S, Moyo, S, Lutucuta, S, Gaseitsiwe, S, Jalloh, S, Andriamandimby, SF, Oguntope, S, Grayo, S, Lekana-Douki, S, Prosolek, S, Ouangraoua, S, van Wyk, S, Schaffner, SF, Kanyerezi, S, Ahuka-Mundeke, S, Rudder, S, Pillay, S, Nabadda, S, Behillil, S, Budiaki, SL, van der Werf, S, Mashe, T, Mohale, T, Le-Viet, T, Velavan, TP, Schindler, T, Maponga, TG, Bedford, T, Anyaneji, UJ, Chinedu, U, Ramphal, U, George, UE, Enouf, V, Nene, V, Gorova, V, Roshdy, WH, Karim, WA, Ampofo, WK, Preiser, W, Choga, WT, Ahmed, YA, Ramphal, Y, Bediako, Y, Naidoo, Y, Butera, Y, de Laurent, ZR, Ouma, AEO, von Gottberg, A, Githinji, G, Moeti, M, Tomori, O, Sabeti, PC, Sall, AA, Oyola, SO, Tebeje, YK, Tessema, SK, de Oliveira, T, Happi, C, Lessells, R, Nkengasong, J, Wilkinson, E, Tegally, H, San, JE, Cotten, M, Moir, M, Tegomoh, B, Mboowa, G, Martin, DP, Baxter, C, Lambisia, AW, Diallo, A, Amoako, DG, Diagne, MM, Sisay, A, Zekri, A-RN, Gueye, AS, Sangare, AK, Ouedraogo, A-S, Sow, A, Musa, AO, Sesay, AK, Abias, AG, Elzagheid, A, Lagare, A, Kemi, A-S, Abar, AE, Johnson, AA, Fowotade, A, Oluwapelumi, AO, Amuri, AA, Juru, A, Kandeil, A, Mostafa, A, Rebai, A, Sayed, A, Kazeem, A, Balde, A, Christoffels, A, Trotter, AJ, Campbell, A, Keita, AK, Kone, A, Bouzid, A, Souissi, A, Agweyu, A, Naguib, A, Gutierrez, A, Nkeshimana, A, Page, AJ, Yadouleton, A, Vinze, A, Happi, AN, Chouikha, A, Iranzadeh, A, Maharaj, A, Batchi-Bouyou, AL, Ismail, A, Sylverken, AA, Goba, A, Femi, A, Sijuwola, AE, Marycelin, B, Salako, BL, Oderinde, BS, Bolajoko, B, Diarra, B, Herring, BL, Tsofa, B, Lekana-Douki, B, Mvula, B, Njanpop-Lafourcade, B-M, Marondera, BT, Khaireh, BA, Kouriba, B, Adu, B, Pool, B, McInnis, B, Brook, C, Williamson, C, Nduwimana, C, Anscombe, C, Pratt, CB, Scheepers, C, Akoua-Koffi, CG, Agoti, CN, Mapanguy, CM, Loucoubar, C, Onwuamah, CK, Ihekweazu, C, Malaka, CN, Peyrefitte, C, Grace, C, Omoruyi, CE, Rafai, CD, Morang'a, CM, Erameh, C, Lule, DB, Bridges, DJ, Mukadi-Bamuleka, D, Park, D, Rasmussen, DA, Baker, D, Nokes, DJ, Ssemwanga, D, Tshiabuila, D, Amuzu, DSY, Goedhals, D, Grant, DS, Omuoyo, DO, Maruapula, D, Wanjohi, DW, Foster-Nyarko, E, Lusamaki, EK, Simulundu, E, Ong'era, EM, Ngabana, EN, Abworo, EO, Otieno, E, Shumba, E, Barasa, E, Ahmed, EB, Ahmed, EA, Lokilo, E, Mukantwari, E, Philomena, E, Belarbi, E, Simon-Loriere, E, Anoh, EA, Manuel, E, Leendertz, F, Taweh, FM, Wasfi, F, Abdelmoula, F, Takawira, FT, Derrar, F, Ajogbasile, F, Treurnicht, F, Onikepe, F, Ntoumi, F, Muyembe, FM, Ragomzingba, FEZ, Dratibi, FA, Iyanu, F-A, Mbunsu, GK, Thilliez, G, Kay, GL, Akpede, GO, van Zyl, GU, Awandare, GA, Kpeli, GS, Schubert, G, Maphalala, GP, Ranaivoson, HC, Omunakwe, HE, Onywera, H, Abe, H, Karray, H, Nansumba, H, Triki, H, Kadjo, HAA, Elgahzaly, H, Gumbo, H, Mathieu, H, Kavunga-Membo, H, Smeti, I, Olawoye, IB, Adetifa, IMO, Odia, I, Ben Boubaker, IB, Mohammad, IA, Ssewanyana, I, Wurie, I, Konstantinus, IS, Halatoko, JWA, Ayei, J, Sonoo, J, Makangara, J-CC, Tamfum, J-JM, Heraud, J-M, Shaffer, JG, Giandhari, J, Musyoki, J, Nkurunziza, J, Uwanibe, JN, Bhiman, JN, Yasuda, J, Morais, J, Kiconco, J, Sandi, JD, Huddleston, J, Odoom, JK, Morobe, JM, Gyapong, JO, Kayiwa, JT, Okolie, JC, Xavier, JS, Gyamfi, J, Wamala, JF, Bonney, JHK, Nyandwi, J, Everatt, J, Nakaseegu, J, Ngoi, JM, Namulondo, J, Oguzie, JU, Andeko, JC, Lutwama, JJ, Mogga, JJH, O'Grady, J, Siddle, KJ, Victoir, K, Adeyemi, KT, Tumedi, KA, Carvalho, KS, Mohammed, KS, Dellagi, K, Musonda, KG, Duedu, KO, Fki-Berrajah, L, Singh, L, Kepler, LM, Biscornet, L, Martins, LDO, Chabuka, L, Olubayo, L, Ojok, LD, Deng, LL, Ochola-Oyier, L, Tyers, L, Mine, M, Ramuth, M, Mastouri, M, ElHefnawi, M, Mbanne, M, Matsheka, M, Kebabonye, M, Diop, M, Momoh, M, Lima Mendonca, MDL, Venter, M, Paye, MF, Faye, M, Nyaga, MM, Mareka, M, Damaris, M-M, Mburu, MW, Mpina, MG, Owusu, M, Wiley, MR, Tatfeng, MY, Ayekaba, MO, Abouelhoda, M, Beloufa, MA, Seadawy, MG, Khalifa, MK, Matobo, MM, Kane, M, Salou, M, Mbulawa, MB, Mwenda, M, Allam, M, Phan, MVT, Abid, N, Rujeni, N, Abuzaid, N, Ismael, N, Elguindy, N, Top, NM, Dia, N, Mabunda, N, Hsiao, N-Y, Silochi, NB, Francisco, NM, Saasa, N, Bbosa, N, Murunga, N, Gumede, N, Wolter, N, Sitharam, N, Ndodo, N, Ajayi, NA, Tordo, N, Mbhele, N, Razanajatovo, NH, Iguosadolo, N, Mba, N, Kingsley, OC, Sylvanus, O, Femi, O, Adewumi, OM, Testimony, O, Ogunsanya, OA, Fakayode, O, Ogah, OE, Oludayo, O-E, Faye, O, Smith-Lawrence, P, Ondoa, P, Combe, P, Nabisubi, P, Semanda, P, Oluniyi, PE, Arnaldo, P, Quashie, PK, Okokhere, PO, Bejon, P, Dussart, P, Bester, PA, Mbala, PK, Kaleebu, P, Abechi, P, El-Shesheny, R, Joseph, R, Aziz, RK, Essomba, RG, Ayivor-Djanie, R, Njouom, R, Phillips, RO, Gorman, R, Kingsley, RA, Neto Rodrigues, RMDESA, Audu, RA, Carr, RAA, Gargouri, S, Masmoudi, S, Bootsma, S, Sankhe, S, Mohamed, SI, Femi, S, Mhalla, S, Hosch, S, Kassim, SK, Metha, S, Trabelsi, S, Agwa, SH, Mwangi, SW, Doumbia, S, Makiala-Mandanda, S, Aryeetey, S, Ahmed, SS, Ahmed, SM, Elhamoumi, S, Moyo, S, Lutucuta, S, Gaseitsiwe, S, Jalloh, S, Andriamandimby, SF, Oguntope, S, Grayo, S, Lekana-Douki, S, Prosolek, S, Ouangraoua, S, van Wyk, S, Schaffner, SF, Kanyerezi, S, Ahuka-Mundeke, S, Rudder, S, Pillay, S, Nabadda, S, Behillil, S, Budiaki, SL, van der Werf, S, Mashe, T, Mohale, T, Le-Viet, T, Velavan, TP, Schindler, T, Maponga, TG, Bedford, T, Anyaneji, UJ, Chinedu, U, Ramphal, U, George, UE, Enouf, V, Nene, V, Gorova, V, Roshdy, WH, Karim, WA, Ampofo, WK, Preiser, W, Choga, WT, Ahmed, YA, Ramphal, Y, Bediako, Y, Naidoo, Y, Butera, Y, de Laurent, ZR, Ouma, AEO, von Gottberg, A, Githinji, G, Moeti, M, Tomori, O, Sabeti, PC, Sall, AA, Oyola, SO, Tebeje, YK, Tessema, SK, de Oliveira, T, Happi, C, Lessells, R, Nkengasong, J, and Wilkinson, E

Abstract

Investment in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing in Africa over the past year has led to a major increase in the number of sequences that have been generated and used to track the pandemic on the continent, a number that now exceeds 100,000 genomes. Our results show an increase in the number of African countries that are able to sequence domestically and highlight that local sequencing enables faster turnaround times and more-regular routine surveillance. Despite limitations of low testing proportions, findings from this genomic surveillance study underscore the heterogeneous nature of the pandemic and illuminate the distinct dispersal dynamics of variants of concern-particularly Alpha, Beta, Delta, and Omicron-on the continent. Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve while the continent faces many emerging and reemerging infectious disease threats. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century.

Published
2022

14. HIV-1 groupe O virus infection in Abidjan, Côte d'Ivoire

Author

Nkengasong, J., Sylla-Koko, F., Peeters, Martine, Ellenberger, D., Sassan-Morokro, M., Ekpini, R.A., Msellati, Philippe, Greenberg, A.E., Combe, P., and Rayfield, M.

Subjects
SIDA, TEST ELISA, TECHNIQUE PCR, VIRUS, SURVEILLANCE EPIDEMIOLOGIQUE, SEROLOGIE, VIRUS HIV-1 GROUPE E O
Published
1998

15. Evaluation of different V3 peptides in an enzyme immunoassay for specific HIV type 1 group 0 antibody detection

Author

Ondoa, P., Willems, B., Fransen, K., Nkengasong, J., Janssens, W., Heyndrickx, L., Zekeng, L., Ndumbe, P., Simon, F., Saragosti, S., Gürtler, L., Peeters, Martine, Korber, B., Goudsmit, J., and Van der Groen, G.

Subjects
EPIDEMIOLOGIE, DIAGNOSTIC, TEST, SIDA, VIRUS, IMMUNOLOGIE, VIH-1 GROUPE O, ANTICORPS
Abstract

Strategies to discriminate group O from group M infections need to be improved. We have developed and evaluated an HIV-1 group O V3 peptide-based enzyme immunoassay (PEIA) for specific HIV-1 group O antibody detection among HIV-1-infected patients. Synthetic peptides, derived from the amino acid sequences of the V3 loop of 15 different group O strains and 7 group O consensus sequences, were evaluated in a PEIA against a panel of genetically confirmed group O (n=33), group M (n=90), and HIV-1 antibody-negative sera (n=17). The best-performing PEIA(s) were then used to screen 134 sera of European and 336 sera of Cameroonian origin for the presence of anti-HIV-1 group O antibodies. The reactivity of reference ("gold standard") sera to individual peptides in the PEIA resulted in the selection of five different peptides with sensitivities (sens), specificities (spec), and test efficiencies (TEs) in the range of 90 to 100%. Improvement of the PEIA was obtained with simultaneous reactivity of at least two different peptides in separate wells of an ELISA plate, together with stringent criteria for positivity. We were able to select seven peptide combinations each with a sens, spec, and TE of 96.9, 100, and 99.2%, respectively. None of the 134 European and 4 (1.2%) of the 336 Cameroonian samples sera were group O positive in the optimized HIV-1 group O PEIA ; this was confirmed by the repeated presence of reactives, in agreement with the present knowledge of group O infection distribution. Finally, we were able to develop a strategy with a higher TE (99.2%) than the previously used ANT-70 (98.5%) and ANT-70/MVP5180 (95.7%). Our results show that optimal specificity rather than optimal sensitivity makes the V3 PEIA a sufficiently accurate epidemiological tool to be useful in estimating specifically group O infection among HIV-1-infected patients. (Résumé d'auteur)

Published
1998

18. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses

Author

Nyambi, P.N., Nkengasong, J., Peeters, Martine, Simon, F., Eberle, J., Janssens, Wouter, Fransen, K., Willems, B., Vereecken, K., Heyndrickx, L., Piot, P., and Van der Groen, G.

Subjects
ANTIGENE, VIRUS HIV-1 GROUPE O, SIDA, Virology, HIV-1, Group M, IMMUNOLOGIE, Neutralizing antibodies, NEUTRALISATION, Group O, SEROLOGIE, VIRUS HIV-1 GROUPE M, ANTICORPS
Published
1995

19. Genetic and phylogenetic analysis of env subtypes G and H in Central Africa

Author

Janssens, W., Heyndrickx, L., Fransen, K., Motte, J., Peeters, M., Nkengasong, J. N., Ndumbe, P. M., Delaporte, E., Perret, J. L., Atende, C., Piot, P., and van der Groen, G.

Subjects
Subtypes, SIDA, PEPTIDE V3, Phylogenetics, Congo-Brazzaville, Congo-Kinshasa, Virology, HIV-1, Genetics, VIRUS, Africa, Central, PHYLOGENIE, Gabon, ANALYSE GENETIQUE
Published
1994

20. Role of the Laboratory in Ensuring Global Access to ARV Treatment for HIV-Infected Children: Consensus Statement on the Performance of Laboratory Assays for Early Infant Diagnosis

Author

Stevens, W., primary, Sherman, G., additional, Downing, R., additional, Parsons, L. M., additional, Ou, C.-Y., additional, Crowley, S., additional, Gershy-Damet, G. M., additional, Fransen, K., additional, Bulterys, M., additional, Homsy, J., additional, Lu, L., additional, Finkbeiner, T., additional, and Nkengasong, J. N., additional

Published
2008
Full Text
View/download PDF

23. Evaluation of a newly developed HIV antigen test

Author

Fransen, K., primary, Mertens, G., additional, Stynen, D., additional, Goris, A., additional, Nys, P., additional, Nkengasong, J., additional, Heyndrickx, L., additional, Janssens, W., additional, and van der Groen, G., additional

Published
1997
Full Text
View/download PDF

25. Reduced Capacity of Antibodies from Patients Infected with Human Immunodeficiency Virus Type 1 (HIV-l) Group 0 to Neutralize Primary Isolates of HIV-1 Group M Viruses

Author

Nyambi, P. N., primary, Nkengasong, J., additional, Peeters, M., additional, Simon, F., additional, Eberle, J., additional, Janssens, W., additional, Fransen, K., additional, Willems, B., additional, Vereecken, K., additional, Heyndrickx, L., additional, Piot, P., additional, and van der Groen, G., additional

Published
1995
Full Text
View/download PDF

27. Hiv-1 Group O Infection in Belgium

Author

Peeters, M., primary, Lobe, V., additional, Nkengasong, J., additional, Willems, B., additional, Delforge, M.L., additional, Van Renterghem, L., additional, Revets, H., additional, Sprecher, S., additional, and Van der Groen, G., additional

Published
1995
Full Text
View/download PDF

28. Cervicovaginal anti-HIV antibodies in HIV-seronegative female sex workers in Abidjan, Côte d'Ivoire.

Author

Ghys, Peter D., Bélec, Laurent, Diallo, Mamadou O., Ettiègne-Traoré, Virginie, Becquart, Pierre, Maurice, Chantal, Nkengasong, John N., Coulibaly, Issa-Malick, Greenberg, Alan E., Laga, Marie, Wiktor, Stefan Z., Ghys, P D, Bélec, L, Diallo, M O, Ettiègne-Traoré, V, Becquart, P, Maurice, C, Nkengasong, J N, Coulibaly, I M, and Greenberg, A E

Published
2000
Full Text
View/download PDF

29. 'Evidence for a High Prevalence of HIV-1 Protease Mutations Associated with Resistance to Protease Inhibitors in HIV-1 Drug-Naive Individuals Worldwide Infected with Subtypes A-G.'

Author

Pieniazek, D., Rayfield, M., Nkengasong, J., Coulibably, I.-M., Wiitor, S.-Z., Sempal, S.-D.-K., Downing, R., Mastro, T., Tanun, A., Hu, D.J., Lal, R., Dondero, T., and Lane, C.

Subjects
Protease inhibitors -- Physiological aspects, HIV (Viruses)
Abstract

D. Pieniazek, M. Rayfield, J. Nkengasong, I.-M. Coulibably, S.-Z. Wiitor, S.-D.-K. Sempal, R. Downing, T. Mastro, A. Tanun, D.J. Hu, R. Lal, T. Dondero and C. Lane. U.S. Centers for [...]

Published
1999

32. Developing a containment laboratory in Sub-Saharan Africa

Author

Richmond, J.Y., Wiktor, S., Weakland, L., Maurice, C., Nkengasong, J., Ellenberger, D., Rayfield, M., Kadio, A., and Greenberg, A.

Subjects
Medical laboratories -- Cote d'Ivoire, HIV infection -- Prevention, Tuberculosis -- Prevention, Cote d'Ivoire -- Health aspects
Abstract

"Developing a Containment Laboratory in Sub-Saharan Africa." J.Y. Richmond, S. Wiktor, L. Weakland, C. Maurice, J. Nkengasong, D. Ellenberger, M. Rayfield, A. Kadio and A. Greenberg. U.S. Centers for Disease [...]

Published
1998

33. Evaluation of a newly developed HIV antigen test

Author

Fransen, K., Mertens, G., Sytnen, D., Goris, A., Nys, P., Nkengasong, J., Heyndrickx, L., Janssens, W., and Vandergroen, G.

Subjects
HIV testing -- Innovations, Enzyme-linked immunosorbent assay -- Evaluation, Diagnostic reagents and test kits -- Evaluation
Abstract

Fransen, K.; Mertens, G.; Stynen, D.; Goris, A.; Nys, P.; Nkengasong, J.; Heyndrickx, L.; Janssens, W.; Vandergroen, G. "Evaluation of a Newly Developed HIV Antigen Test." Journal of Medical Virology, [...]

Published
1997

34. Genetic diversity of HIV-1 in Abidjan, Cote d'Ivoire

Author

Ellenberger, D., Pieniazek, D., Luo, C.-C., Nkengasong, J., Maurice, C., Janini, M., Ramos, A., Hu, D., Coulibaly, I.-M., Ekpini, E., Wiktor, S., Greenberg, A., Schochetmar, G., and Rayfield, M.

Subjects
HIV (Viruses) -- Genetic aspects
Abstract

According to an abstract submitted by the authors to the Keystone Symposia on Molecular and Cellular Biology entitled AIDS Pathogenesis, sponsored by Abbott Laboratories and the Director's Sponsor Fund, held [...]

Published
1997

37. Genetic diversity of HIV: implications for diagnosis, therapy and prevention of mother-to-child transmission

Author

Zeh, C.E., Lange, J.M.A., Nkengasong, J., Ondoa, P.L.A., and Faculteit der Geneeskunde

Abstract

Clement Zeh deed in Nigeria onderzoek naar de genetische diversiteit van hiv, het virus dat aids veroorzaakt. Hij bekeek de gevolgen van de diversiteit voor de diagnose en de behandeling. Ook is kennis van de diversiteit van belang bij het ontwerpen van een vaccin dat effectief is tegen alle hiv-stammen die in ontwikkelingslanden circuleren. In Nigeria domineren hiv1-subtype A en G. Zeh demonstreerde dat een snelle test geschikt is voor een breed spectrum van hiv-stammen.

Published
2010

40. Strengthening and expanding capacities in clinical trials: advancing pandemic prevention, preparedness and response in Africa.

Author

Ndembi N, Mekonen TT, Folayan MO, Dereje N, Kruger A, Fokam J, Temfack E, Raji T, Nachega J, Boum Y 2nd, Crowell TA, Ngongo AN, Mboup S, Ntoumi F, Loots G, Makanga M, Sow S, Karim SA, and Nkengasong J

Subjects
Humans, Africa epidemiology, SARS-CoV-2, Capacity Building, COVID-19 prevention & control, COVID-19 epidemiology, COVID-19 virology, Pandemics prevention & control, Clinical Trials as Topic
Published
2024
Full Text
View/download PDF

42. Genomic surveillance of SARS-CoV-2 reveals highest severity and mortality of delta over other variants: evidence from Cameroon.

Author

Fokam J, Essomba RG, Njouom R, Okomo MA, Eyangoh S, Godwe C, Tegomoh B, Otshudiema JO, Nwobegahay J, Ndip L, Akenji B, Takou D, Moctar MMM, Mbah CK, Ndze VN, Maidadi-Foudi M, Kouanfack C, Tonmeu S, Ngono D, Nkengasong J, Ndembi N, Bissek AZK, Mouangue C, Ndongo CB, Epée E, Mandeng N, Kamso Belinga S, Ayouba A, Fernandez N, Tongo M, Colizzi V, Halle-Ekane GE, Perno CF, Ndjolo A, Ndongmo CB, Shang J, Esso L, de-Tulio O, Diagne MM, Boum Y 2nd, Mballa GAE, and Njock LR

Subjects
Humans, Cameroon epidemiology, Genomics, SARS-CoV-2 genetics, COVID-19 epidemiology
Abstract

While the SARS-CoV-2 dynamic has been described globally, there is a lack of data from Sub-Saharan Africa. We herein report the dynamics of SARS-CoV-2 lineages from March 2020 to March 2022 in Cameroon. Of the 760 whole-genome sequences successfully generated by the national genomic surveillance network, 74% were viral sub-lineages of origin and non-variants of concern, 15% Delta, 6% Omicron, 3% Alpha and 2% Beta variants. The pandemic was driven by SARS-CoV-2 lineages of origin in wave 1 (16 weeks, 2.3% CFR), the Alpha and Beta variants in wave 2 (21 weeks, 1.6% CFR), Delta variants in wave 3 (11 weeks, 2.0% CFR), and omicron variants in wave 4 (8 weeks, 0.73% CFR), with a declining trend over time (p = 0.01208). Even though SARS-CoV-2 heterogeneity did not seemingly contribute to the breadth of transmission, the viral lineages of origin and especially the Delta variants appeared as drivers of COVID-19 severity in Cameroon., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

43. Sustaining the HIV/AIDS response: PEPFAR's vision.

Author

Nkengasong J, Ruffner M, Bartee M, Katz IT, and Reid MJA

Subjects
Humans, International Cooperation, Program Evaluation, Acquired Immunodeficiency Syndrome drug therapy, Acquired Immunodeficiency Syndrome epidemiology, Acquired Immunodeficiency Syndrome prevention & control, HIV Infections drug therapy, HIV Infections epidemiology, HIV Infections prevention & control
Published
2023
Full Text
View/download PDF

45. Prioritizing Mental Health in the HIV/AIDS Response in Africa.

Author

Godfrey C and Nkengasong J

Subjects
Humans, Africa epidemiology, Developing Countries, South Africa, Acquired Immunodeficiency Syndrome epidemiology, Acquired Immunodeficiency Syndrome prevention & control, Acquired Immunodeficiency Syndrome psychology, HIV Infections epidemiology, HIV Infections prevention & control, HIV Infections psychology, Mental Health
Published
2023
Full Text
View/download PDF

46. PEPFAR at 20-Looking Back and Looking Ahead.

Author

Nkengasong J, Zaidi I, and Katz IT

Subjects
Humans, United States, History, 21st Century, Acquired Immunodeficiency Syndrome drug therapy, Acquired Immunodeficiency Syndrome history, Acquired Immunodeficiency Syndrome therapy, HIV Infections drug therapy, HIV Infections history, HIV Infections therapy, International Cooperation
Published
2023
Full Text
View/download PDF

48. A continent-wide effort and solidarity at curbing COVID-19 pandemic: the Africa task force for novel coronavirus (AFTCOR) infection prevention and control technical working group's experience.

Author

Paintsil E, Alimi Y, Abdulaziz M, Ogbuagu O, Ogunsola F, Kessy SJ, Horsney E, Lee C, Brundney K, Okwor T, Kabwe P, Waheed A, Vondran A, Bigirimana R, Ilesanmi O, Nsubuga DN, Raji T, Mankoula W, Ihekweazu C, and Nkengasong J

Subjects
Infection Control, Humans, Pandemics, Africa epidemiology, COVID-19 prevention & control
Abstract

A continent-wide Africa Task Force for Coronavirus with its six technical working groups was formed to prepare adequately and respond to the novel Coronavirus disease (COVID-19) outbreak in Africa. This research in practice article aimed to describe how the infection prevention and control (IPC) technical working group (TWG) supported Africa Centre for Disease Control and Prevention (Africa CDC) in preparedness and response to COVID-19 on the continent. To effectively address the multifaceted IPC TWG mandate of organizing training and implementing rigorous IPC measures at healthcare service delivery points, the working group was sub-divided into four sub-groups-Guidelines, Training, Research, and Logistics. The action framework was used to describe the experiences of each subgroup. The guidelines subgroup developed 14 guidance documents and two advisories; all of which were published in English. In addition, five of these documents were translated and published in Arabic, while three others were translated and published in French and Portuguese. Challenges faced in the guidelines subgroup included the primary development of the Africa CDC website in English, and the need to revise previously issued guidelines. The training subgroup engaged the Infection Control Africa Network as technical experts to carry out in-person training of IPC focal persons and port health personnel across the African continent. Challenges faced included the difficulty in conducting face-to-face IPC training and onsite technical support due to the lockdown. The research subgroup developed an interactive COVID-19 Research Tracker on the Africa CDC website and conducted a context-based operation and implementation research. The lack of understanding of Africa CDC's capacity to lead her own research was the major challenge faced by the research subgroup. The logistics subgroup assisted African Union (AU) member states to identify their IPC supply needs through capacity building for IPC quantification. A notable challenge faced by the logistics subgroup was the initial lack of experts on IPC logistics and quantifications, which was later addressed by the recruitment of professionals. In conclusion, IPC cannot be built overnight nor can it be promoted abruptly during outbreaks of diseases. Thus, the Africa CDC should build strong national IPC programmes and support such programmes with trained and competent professionals., (© 2023. The Author(s).)

Published
2023
Full Text
View/download PDF

50. Vital Signs: Progress Toward Eliminating HIV as a Global Public Health Threat Through Scale-Up of Antiretroviral Therapy and Health System Strengthening Supported by the U.S. President's Emergency Plan for AIDS Relief - Worldwide, 2004-2022.

Author

Chun HM, Dirlikov E, Cox MH, Sherlock MW, Obeng-Aduasare Y, Sato K, Voetsch AC, Ater AD, Romano ER, Tomlinson H, Modi S, Achrekar A, and Nkengasong J

Subjects
Vital Signs, Humans, Male, Female, Pregnancy, Public Health, International Cooperation, Vulnerable Populations, Child, Adolescent, Young Adult, Adult, HIV Infections drug therapy, HIV Infections epidemiology, HIV Infections prevention & control, Anti-Retroviral Agents therapeutic use, Viral Load drug effects
Abstract

Introduction: In 2004, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), with CDC as a major U.S. government implementing agency, began providing HIV antiretroviral therapy (ART) worldwide. Through suppression of HIV viral load, effective ART reduces morbidity and mortality among persons with HIV infection and prevents vertical and sexual transmission., Methods: To describe program impact, data were analyzed from all PEPFAR programs and from six countries that have conducted nationally representative Population-based HIV Impact Assessment (PHIA) surveys, including PEPFAR programmatic data on the number of persons with HIV infection receiving PEPFAR-supported ART (2004-2022), rates of viral load coverage (the proportion of eligible persons with HIV infection who received a viral load test) and viral load suppression (proportion of persons who received a viral load test with <1,000 HIV copies per mL of blood) (2015-2022), and population viral load suppression rates in six countries that had two PHIA surveys conducted during 2015-2021. To assess health system strengthening, data on workforce and laboratory systems were analyzed., Results: By September 2022, approximately 20 million persons with HIV infection in 54 countries were receiving PEPFAR-supported ART (62% CDC-supported); this number increased 300-fold from the 66,550 reported in September 2004. During 2015-2022, viral load coverage more than tripled, from 24% to 80%, and viral load suppression increased from 80% to 95%. Despite increases in viral load suppression rates and health system strengthening investments, variability exists in viral load coverage among some subpopulations (children aged <10 years, males, pregnant women, men who have sex with men [MSM], persons in prisons and other closed settings [persons in prisons], and transgender persons) and in viral load suppression among other subpopulations (pregnant and breastfeeding women, persons in prisons, and persons aged <20 years)., Conclusions and Implications for Public Health Practice: Since 2004, PEPFAR has scaled up effective ART to approximately 20 million persons with HIV infection in 54 countries. To eliminate HIV as a global public health threat, achievements must be sustained and expanded to reach all subpopulations. CDC and PEPFAR remain committed to tackling HIV while strengthening public health systems and global health security., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results